http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113016782-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N1-0226 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N1-021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
| filingDate | 2021-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113016782-B |
| titleOfInvention | A kind of cell preservation solution and its preparation method and application |
| abstract | The invention discloses a cell preservation solution and a preparation method and application thereof, in particular to a mesenchymal stem cell, NK cell, and CART cell preservation solution and a preparation method and application thereof. A cell preservation solution, the content of each component is as follows: every 100ml of the cell preservation solution contains 5-15ml of human serum albumin, 80-90ml of compound electrolyte injection, and compound amino acid injection 1 without sulfite antioxidants -5ml, L-glutamine 0.01-1g, anhydrous glucose 0.1-1g. The preservation solution of the invention maintains a cell viability rate of not less than 80% for 144 hours or more, agglomeration rate of less than 12%, greatly prolongs the preservation time of the cell preparation, and can realize the possibility of application in the whole country and even the world. All the components used in the present invention are clinical grade medicines, and the clinical application is safe and reliable. |
| priorityDate | 2021-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 67.